Tags

Type your tag names separated by a space and hit enter

Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats.
Am J Kidney Dis. 1998 Oct; 32(2 Suppl 2):S40-7.AJ

Abstract

The active metabolite of vitamin D, calcitriol [1,25(OH)2D3] suppresses parathyroid hormone (PTH) gene transcription and PTH secretion. Although 1,25(OH)2D3 is effective in suppressing secondary hyperparathyroidism in uremic patients, the mandatory use of large amounts of calcium salts to control serum phosphorus may preclude in some patients the use of ideal therapeutic doses of 1,25(OH)2D3 because of hypercalcemia. We have studied a new analogue of calcitriol,19-nor-1,25(OH)2D2 that possesses low calcemic and phosphatemic activity. We have clearly demonstrated that this analogue of calcitriol can suppress secondary hyperparathyroidism without inducing hypercalcemia or hyperphosphatemia in uremic rats. In addition, this analogue of vitamin D supresses pre-pro PTH messenger RNA in a similar fashion to that of 1,25(OH)2D3. Contrary to the effect of 1,25(OH)2D3 that increases the intestinal vitamin D receptor, this analogue of vitamin D suppresses the intestinal vitamin D receptor. This finding may be critical for the lack of calcemic activity of 19-nor-1,25(OH)2D2 seen in these studies. One of the explanations for the lack of an increasing intestinal VDR is the fact that 19-nor-1,25(OH)2D2 decreases endogenous levels of 1,25(OH)2D3. In summary, we have shown that 19-nor-1,25(OH)2D2, a new analogue of calcitriol is effective in suppressing PTH in uremic rats with secondary hyperparathyroidism. In addition, there is a significant decrease in the VDR in the intestine, which may explain in part the less calcemic and hyperphosphatemic effect of this analogue.

Authors+Show Affiliations

Renal Division, Washington University School of Medicine, St Louis, MO 63110, USA. eslatopo@imgate.wustl.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

9808142

Citation

Slatopolsky, E, et al. "Effects of 19-nor-1,25(OH)2D2, a New Analogue of Calcitriol, On Secondary Hyperparathyroidism in Uremic Rats." American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation, vol. 32, no. 2 Suppl 2, 1998, pp. S40-7.
Slatopolsky E, Finch J, Ritter C, et al. Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats. Am J Kidney Dis. 1998;32(2 Suppl 2):S40-7.
Slatopolsky, E., Finch, J., Ritter, C., & Takahashi, F. (1998). Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation, 32(2 Suppl 2), S40-7.
Slatopolsky E, et al. Effects of 19-nor-1,25(OH)2D2, a New Analogue of Calcitriol, On Secondary Hyperparathyroidism in Uremic Rats. Am J Kidney Dis. 1998;32(2 Suppl 2):S40-7. PubMed PMID: 9808142.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats. AU - Slatopolsky,E, AU - Finch,J, AU - Ritter,C, AU - Takahashi,F, PY - 1998/11/10/pubmed PY - 1998/11/10/medline PY - 1998/11/10/entrez SP - S40 EP - 7 JF - American journal of kidney diseases : the official journal of the National Kidney Foundation JO - Am. J. Kidney Dis. VL - 32 IS - 2 Suppl 2 N2 - The active metabolite of vitamin D, calcitriol [1,25(OH)2D3] suppresses parathyroid hormone (PTH) gene transcription and PTH secretion. Although 1,25(OH)2D3 is effective in suppressing secondary hyperparathyroidism in uremic patients, the mandatory use of large amounts of calcium salts to control serum phosphorus may preclude in some patients the use of ideal therapeutic doses of 1,25(OH)2D3 because of hypercalcemia. We have studied a new analogue of calcitriol,19-nor-1,25(OH)2D2 that possesses low calcemic and phosphatemic activity. We have clearly demonstrated that this analogue of calcitriol can suppress secondary hyperparathyroidism without inducing hypercalcemia or hyperphosphatemia in uremic rats. In addition, this analogue of vitamin D supresses pre-pro PTH messenger RNA in a similar fashion to that of 1,25(OH)2D3. Contrary to the effect of 1,25(OH)2D3 that increases the intestinal vitamin D receptor, this analogue of vitamin D suppresses the intestinal vitamin D receptor. This finding may be critical for the lack of calcemic activity of 19-nor-1,25(OH)2D2 seen in these studies. One of the explanations for the lack of an increasing intestinal VDR is the fact that 19-nor-1,25(OH)2D2 decreases endogenous levels of 1,25(OH)2D3. In summary, we have shown that 19-nor-1,25(OH)2D2, a new analogue of calcitriol is effective in suppressing PTH in uremic rats with secondary hyperparathyroidism. In addition, there is a significant decrease in the VDR in the intestine, which may explain in part the less calcemic and hyperphosphatemic effect of this analogue. SN - 0272-6386 UR - https://www.unboundmedicine.com/medline/citation/9808142/Effects_of_19_nor_125_OH_2D2_a_new_analogue_of_calcitriol_on_secondary_hyperparathyroidism_in_uremic_rats_ L2 - https://www.lens.org/lens/search?q=citation_id:9808142 DB - PRIME DP - Unbound Medicine ER -